Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 152 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Proton Pump Inhibitors Clear all
Completed Phase 3 Interventional

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

NCT00389948
View directory record Official record
Conditions
Heartburn
Interventions
Lanzoprazole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Hoover, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2007 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

NCT03130556
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, High Fat, High Calorie Meal, Rabeprazole
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

NCT05581992
View directory record Official record
Conditions
Healthy Participants
Interventions
AMG 510, Omeprazole
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 22, 2026, 4:20 AM EDT
Completed No phase listed Observational

Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU)

NCT00919152
View directory record Official record
Conditions
Stress Ulcer Prophylaxis
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Omeprazole Decrease Intestinal Calcium Absorption?

NCT00582972
View directory record Official record
Conditions
Osteoporosis, Achlorhydria, GERD, Hip Fracture
Interventions
Omeprazole
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jul 22, 2026, 4:20 AM EDT
Terminated Phase 3 Interventional

Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor

NCT00161200
View directory record Official record
Conditions
Esophageal Metaplasia
Interventions
Ranitidine & Pantoprazole
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Jul 22, 2026, 4:20 AM EDT
Not yet recruiting Not applicable Interventional

A Comparison of Cosmos Rx Medication Adherence Platform vs. Pharmacy Fill Adherence Measures

NCT07712614
View directory record Official record
Conditions
GERD (Gastroesophageal Reflux Disease)
Interventions
Fortiskap
Device
Lead sponsor
Cosmos Rx, Inc
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gastric pH and Anthocyanin Absorption

NCT01122160
View directory record Official record
Conditions
Anthocyanin Metabolism
Interventions
omeprazole, placebo
Drug
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
22 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Jul 22, 2026, 4:20 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux

NCT00369265
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Lansoprazole, Sugar pill
Drug · Dietary Supplement
Lead sponsor
American Institute for Voice and Ear Research
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)

NCT06619314
View directory record Official record
Conditions
Healthy
Interventions
Calderasib, PPI
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 22, 2026, 4:20 AM EDT
Not listed Phase 1 Interventional

The Effect of Nexium on Transmucosal Esophageal Leak

NCT00216788
View directory record Official record
Conditions
Reflux, Esophagitis, Barrett's Esophagus
Interventions
Esomeprazole (Nexium) 40 mg/day
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2010 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 2 Interventional

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

NCT02030925
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
IW-3718, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
North Little Rock, Arkansas • Anaheim, California • Monroe, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jul 22, 2026, 4:20 AM EDT
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

NCT01865825
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Esophageal Barium Xray
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)

NCT03551691
View directory record Official record
Conditions
Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Omeprazole 20mg Capsule, Placebo oral capsule
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Gastric Acid on Colonic Microbiome

NCT01901276
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Omeprazole 40 mg bid
Drug
Lead sponsor
Daniel Freedberg, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program

NCT03719170
View directory record Official record
Conditions
Proton Pump Inhibitors
Interventions
PPI De-prescribing Program
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
220,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
West Haven, Connecticut • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Not applicable Interventional Results available

A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion

NCT00546117
View directory record Official record
Conditions
Otitis Media With Effusion
Interventions
lansoprazole, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 4 Interventional Results available

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

NCT02505945
View directory record Official record
Conditions
GERD Gastroesophageal Reflux Disease
Interventions
Omeprazole, LINX Reflux Management System
Drug · Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
21
States / cities
Mobile, Alabama • Heber Springs, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

NCT01265550
View directory record Official record
Conditions
GERD
Interventions
Nissen fundoplication, baclofen, Desipramine
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers

NCT05497557
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Omeprazole, Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Jul 22, 2026, 4:20 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

NCT05517928
View directory record Official record
Conditions
Healthy
Interventions
Omeprazole, Lactobacillus rhamnosus GG, Placebo
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC

NCT00746733
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lisdexamfetamine Dimesylate, Adderall XR (mixed salts amphetamine)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 22, 2026, 4:20 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

NCT03812380
View directory record Official record
Conditions
Osteoporosis, Hypomagnesemia
Interventions
EffCaMgCit, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

NCT00992589
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 11 Months
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Jul 22, 2026, 4:20 AM EDT